SignalCorporate
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
XFOR topped Q3 revenue estimates despite reporting a loss.
Context
What happened: X4 Pharmaceuticals ($XFOR) reported a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a $0.19 loss, and revenue of $2.88 million that beat the consensus estimate.
Key numbers: Loss per share $0.16 vs. estimate $0.19; year-ago loss $0.69. Earnings surprise +15.79%.
Why it matters: The report marks the fourth straight quarter the company surpassed consensus EPS estimates and the third time it topped revenue estimates in four quarters. The favorable estimate revisions trend ahead of the release translates into a Zacks Rank #2 (Buy).
Market: +13.1% today ($258.38), +737.3% YTD, 0.7x vol — as of 00:45 UTC
Verified: Q3_2026 (Nov 6) revenue $905.9M vs $905.9M est; next print ~Feb 5
What changed
X4 Pharmaceuticals ($XFOR) reported a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a $0.19 loss, and revenue of $2.88 million that beat the consensus estimate.
Why it matters
The report marks the fourth straight quarter the company surpassed consensus EPS estimates and the third time it topped revenue estimates in four quarters. The favorable estimate revisions trend ahead of the release translates into a Zacks Rank #2 (Buy).
Market: +13.1% today ($258.38), +737.3% YTD, 0.7x vol — as of 00:45 UTC
Verified: Q3_2026 (Nov 6) revenue $905.9M vs $905.9M est; next print ~Feb 5